Giuliani, a pharmaceutical company, completed the acquisition of Biogena, a dermatological product company. Financial terms were not disclosed. “The acquisition of the Biogena line is part of Giuliani's development strategy, which hinges both on the organic growth of our leading brands and on the acquisition of external strategic assets that contribute to strengthening the presence and relevance of the Group among pharmacists , the medical profession and consumers," Gaetano Colabucci, Giuliani General Director.